Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1480 (LINC01480) is a long non-coding RNA identified as a hub gene correlating with immune cell infiltration in coronary artery disease and ischemic cardiomyopathy. Upregulation of LINC01480 is associated with protective roles, notably promoting M2 macrophage populations, which have anti-inflammatory effects in cardiac tissues. It is also implicated in regulating immune pathways and metabolic signaling, including downregulation of the mTOR and insulin pathways, suggesting a complex role in cardiovascular and metabolic disease pathogenesis. LINC01480’s expression stratifies cardiovascular disease patients and correlates with cancer immune microenvironments, making it a candidate biomarker and potential therapeutic target. However, no direct drug interactions are documented, and further clinical and experimental validation is required before therapeutic application.
Modulates immune cell infiltration, potentially protecting against disease progression by increasing anti-inflammatory M2 macrophages. Downregulates mTOR and insulin signaling pathways, which may reduce risk of metabolic complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1480 (LINC01480).